

REMARKS

Applicants have reviewed and carefully considered the Restriction Requirement of August 13, 2008. The Examiner has required that because claims 1, 9 and 10 are generic and are directed to several patentably distinct species, as disclosed in dependant claims 2-7, Applicant must elect one species from the following therapeutic agents: protease-controlling agent; growth factor; antibacterial agent; pain-relieving agent; enzymatic agent; and proteolytic enzyme, for prosecution on the merits.

In response to the above Restriction Requirement, Applicant elects the protease-controlling agent of claim 2, without traverse.


It is believed that a full and complete response has been made to the outstanding Restriction Requirement and, as such, the present application is in condition for examination on the merits and allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Atty. Dkt. No.: P70954US0  
Serial No.: 11/272,018

Respectfully submitted,

JACOBSON HOLMAN PLLC

By

A handwritten signature in black ink, appearing to read "J Contrera", is written over the printed name and registration number.

Joseph G. Contrera  
Reg. No. 44,628

400 Seventh Street, N.W.  
Washington, D.C. 20004-2201  
(202) 638-6666  
Date: September 12, 2008  
HBJ/JGC/tg

R:\jcontrera\Coloplast - 11072\P71122US0 Response to RR 9-12-08.doc